ArticlePLoS pathogens2025
In vitro cultured malaria hypnozoites leave a footprint of specific metabolites.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Plasmodium vivax malaria control and elimination is complicated by the presence of dormant liver stages, known as hypnozoites, that can reactivate weeks, months or years after infection giving rise to clinical and transmissible vivax malaria, without exposure to new infectious mosquito bites. Hypnozoite infection remains without symptoms and there are no diagnostic tools available to identify hypnozoite carriers. Such diagnostic tools are invaluable for precise mapping of the scale of the infection problem and for identifying individuals that would qualify for targeted drug treatment, to wipe out this hidden reservoir of malaria parasites. Targeted treatment would have considerable benefits as it would prevent the exposure of individuals without hypnozoites to the considerable side-effects of drugs such as Primaquine, which has a relatively high toxicity to people deficient in glucose-6-phosphate dehydrogenase. Here we present a Proof-of-Concept study aimed at identifying diagnostic markers for malaria hypnozoite infection, by combining in vitro Plasmodium cynomolgi hypnozoite cultures (an accessible proxy to P. vivax with nearly identical biology) with sensitive metabolomics. Specific hypnozoite-related metabolites have been identified in the supernatant of hypnozoite-enriched in vitro liver stage cultures. This suggests that, following in vivo validation of such metabolites in the P. cynomolgi/rhesus monkey model and subsequent in P. vivax-infected individuals, a rapid diagnostic test for hypnozoite infection may be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.